Deferiprone
| Evidence Level: L4 | Predicted Indications: 8 |
Table of Contents
Deferiprone: From Iron Overload in Thalassemia to Hepatic Porphyria
One-Sentence Summary
Deferiprone is an oral iron chelator, originally used to treat iron overload in thalassemia and related blood disorders. The TxGNN model predicts it may be effective for hepatic porphyria, but there are currently 0 registered clinical trials and only 2 publications (one case-level report and one animal study) supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Hemosiderosis, beta-thalassemia (several subtypes), hemoglobinopathy (Health Canada indication text not available) |
| Predicted New Indication | Hepatic porphyria |
| TxGNN Prediction Score | 0.9920 |
| Evidence Level | L4 |
| Canada Market Status | Marketed (marketed DINs: 5 of 5) |
| Number of DINs | 5 (marketed: 5) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, deferiprone is an oral iron chelator whose efficacy in iron overload from thalassemia and related disorders is established, and mechanistically it may be applicable to porphyrias in which iron plays a role.
In some porphyrias, excess iron and iron-driven oxidative stress worsen the build-up of porphyrins. Lowering labile iron could therefore reduce porphyrin accumulation. A 2007 mouse study of a porphyria cutanea tarda-type model and a 2020 report in congenital erythropoietic porphyria are consistent with this idea.
This evidence is preclinical or indirect, and it concerns specific porphyria subtypes rather than hepatic porphyria as a whole. The prediction should be treated as a research question, not an established use.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 32678895 | 2020 | Preclinical / case-level | Blood | Iron chelation rescued hemolytic anemia and skin photosensitivity in congenital erythropoietic porphyria |
| 17854053 | 2007 | Animal study | Hepatology | In a mouse model of porphyria cutanea tarda, deferiprone and iron-deficient diets were compared for effects on liver uroporphyrin accumulation |
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02536579 | FERRIPROX MR | Not available | Not available |
| 02436531 | FERRIPROX | Not available | Not available |
| 02436558 | FERRIPROX | Not available | Not available |
| 02553112 | TARO-DEFERIPRONE | Not available | Not available |
| 02436523 | FERRIPROX | Not available | Not available |
Safety Considerations
- Drug Interactions: The interaction screen returned 100 records; the 20 shown are all rated Moderate. They are mainly polyvalent metal-containing products, which may bind the chelator and reduce its effect:
- Calcium salts (phosphate, acetate, carbonate, citrate, gluconate, lactate, glubionate)
- Magnesium salts and antacids (oxide, carbonate, chloride, citrate, gluconate, hydroxide, sulfate, magaldrate)
- Aluminum hydroxide
- Iron
- Kaolin and attapulgite
- Sucralfate
Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction score is high, but there are no clinical trials and the literature is limited to one case-level report and one mouse study in specific porphyria subtypes. The evidence is preclinical (L4), so this is a research question rather than a candidate ready for clinical development.
To proceed, the following is needed:
- Package insert warnings and contraindications from Health Canada, which are needed before any safety screening
- Mechanism of action data for deferiprone
- Clearer evidence on which porphyria subtypes may benefit, ideally from human studies
- Review of the other predicted indications, which have no supporting trials or literature:
- Primitive portal vein thrombosis, idiopathic copper-associated cirrhosis, early-onset familial noncirrhotic portal hypertension, hepatoportal sclerosis and hepatopulmonary syndrome have no plausible link to iron chelation.
- Pyruvate kinase deficiency and hereditary pyropoikilocytosis have a plausible but untested rationale based on iron overload from chronic hemolysis.
- Beta-thalassemia with other manifestations largely overlaps with an existing indication.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.